A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients with Bladder Cancer (MK-2870-027)

Trial Identifier: 2870-027
Sponsor: MSD
Start Date: December 2024
Primary Completion Date: June 2026
Study Completion Date: July 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2M9
Canada, QC Sherbrooke, QC, Canada, J1H 5N4
France, Nord Lille, Nord, France, 59037
France, Val-de-Marne Creteil, Val-de-Marne, France, 94010
France, Val-de-Marne Villejuif, Val-de-Marne, France, 94805
Netherlands, Zuid-Holland Rotterdam, Zuid-Holland, Netherlands, 3015 GD
Spain, Andalucia Malaga, Andalucia, Spain, 29010
Spain, Madrid Madrid, Spain, 28041
United Kingdom, London, City of London, London, City of, United Kingdom, EC1A 7BE
United States, CA Bakersfield, CA, United States, 93301
United States, FL Tampa, FL, United States, 33612
United States, IL Chicago, IL, United States, 60611
United States, MD Baltimore, MD, United States, 21287